Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Asabys Partners is a venture capital firm established in Barcelona, Spain, specializing in healthcare and life sciences innovation. Founded by Josep Ll. Sanfeliu and Clara Campàs, the firm has built a reputation for integrating environmental, social, and governance (ESG) considerations into its investment processes. This alignment with the United Nations Sustainable Development Goals (SDGs) reflects a commitment to responsible investing.
Currently, Asabys Partners manages a portfolio of 25 companies, focusing on disruptive technologies that aim to improve health outcomes globally. The firm operates from its office located at Via Laietana, 26, 5th floor, 08003 Barcelona, Spain. Asabys Partners has established itself as a key player in the European healthcare investment landscape, actively seeking opportunities that align with its mission.
Asabys Partners invests primarily in the healthcare sector, targeting disruptive and transformative technologies. The firm emphasizes the importance of ESG considerations in its investment strategy, ensuring that its practices align with the United Nations Sustainable Development Goals (SDGs). This focus on responsible investing sets Asabys Partners apart in the venture capital space.
The firm seeks to identify and support innovations that can significantly enhance health outcomes. Asabys Partners is particularly interested in companies that are advancing technologies in various healthcare domains, including women's health and medical devices. Their investment strategy includes a preference for early to growth-stage companies that demonstrate potential for substantial impact in the healthcare sector.
Asabys Partners has a diverse portfolio of 25 companies, showcasing its commitment to healthcare innovation. Notable portfolio companies include:
Josep Ll. Sanfeliu - Co-founder and Managing Partner. He has extensive experience in venture capital and healthcare investments.
Clara Campàs - Co-founder and Managing Partner. Clara brings a strong background in life sciences and investment strategy.
Sylvain Sachot - Partner. Sylvain has a track record in healthcare investments and strategic partnerships.
Guillem Masferrer - Partner. Guillem specializes in biotech and has led several successful investments in the sector.
Montse Vendrell - Partner. Montse focuses on operational support and portfolio management.
Jose María Fernández - Partner. He has expertise in market analysis and investment evaluation.
Emilio Erazo-Fischer - Operating Partner. Emilio provides operational insights and guidance to portfolio companies.
Núria Aloy - CFO. Núria oversees financial operations and strategy.
Maite Malet - Principal. Maite focuses on deal sourcing and portfolio development.
Isabel Jimenez - Principal. Isabel specializes in healthcare investments and market research.
Antonio Limatola - Senior Associate. Antonio supports due diligence and investment analysis.
Anna Bellmunt - Senior Associate. Anna focuses on portfolio management and operational support.
Beatriz Gandarias - Senior Associate. Beatriz assists in deal sourcing and market evaluation.
Joana Correia - Senior Analyst. Joana conducts research and analysis on potential investments.
Diana Araoz - Financial Controller. Diana manages financial reporting and compliance.
Pilar Almajano - Financial Controller. Pilar oversees budgeting and financial planning.
Mònica Sabé - Executive Assistant - Office Manager. Mònica supports daily operations and administrative tasks.
Laia Romero - Executive Assistant. Laia assists with office management and coordination.
To pitch to Asabys Partners, founders should send their proposals via email to contact@asabys.com. It is important to include a comprehensive deck that outlines the business model, market opportunity, and alignment with the firm's investment focus.
In early 2026, Asabys Partners has been actively highlighting significant developments within its portfolio companies. Notable updates include leadership appointments at Medasense and positive Phase 1 results from Agomab.
The firm continues to publish blog posts that showcase advancements in clinical trials and other innovations, demonstrating its commitment to keeping stakeholders informed about the progress of its investments.
What are Asabys Partners' investment criteria?
Asabys Partners focuses on healthcare and life sciences innovations, particularly those that are disruptive and transformative. The firm emphasizes ESG considerations and seeks companies that align with the United Nations Sustainable Development Goals.
How can founders apply or pitch to Asabys Partners?
Founders can pitch to Asabys Partners by sending an email to contact@asabys.com. It is advisable to include a detailed business plan and information on how the startup aligns with the firm's investment focus.
What makes Asabys Partners different from other venture capital firms?
The firm integrates ESG considerations into its investment processes, which is a key differentiator. This commitment to responsible investing aligns with global sustainability goals, making them a unique partner for healthcare innovators.
What is the geographic scope of Asabys Partners' investments?
Asabys Partners primarily invests in Europe, focusing on companies that are advancing healthcare technologies within this region.
What is the typical check size for investments?
While specific check sizes are not disclosed, Asabys Partners typically invests in early to growth-stage companies, which suggests a range that accommodates various stages of development.
What type of post-investment involvement does Asabys Partners have?
The firm actively engages with its portfolio companies, providing support in strategic decision-making and operational guidance to help them achieve their growth objectives.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.